VTRS Viatris Inc

$12.54

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Viatris (VTRS) is poised to release its earnings on November 6, 2025, with investors keenly watching for signs of stability and growth in the pharmaceutical sector. The company, with a market cap of approximately $11.88 billion, is expected to report an EPS of $0.62, closely aligned with the whisper number of $0.63, suggesting a consensus among analysts for steady performance. Revenue is projected to reach $3.62 billion, reflecting Viatris' ongoing efforts to streamline operations and capitalize on its diverse portfolio of generic and specialty medications. Despite the lack of recent news, the market sentiment remains cautiously optimistic, as stakeholders anticipate that Viatris' strategic initiatives, such as cost management and potential new product launches, will bolster its financial health. This earnings report will be crucial in assessing whether Viatris can maintain its trajectory amidst a competitive landscape and deliver on investor expectations.

Updated On 12/31/2025

About Viatris Inc

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Website: https://www.viatris.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1792044
Address
235 EAST 42ND STREET, NEW YORK, NY, US
Valuation
Market Cap
$9.02B
P/E Ratio
nan
PEG Ratio
0.13
Price to Book
0.48
Performance
EPS
$-0.53
Dividend Yield
6.35%
Profit Margin
-4.30%
ROE
-3.24%
Technicals
50D MA
$9.33
200D MA
$11.22
52W High
$13.38
52W Low
$6.85
Fundamentals
Shares Outstanding
1B
Target Price
$12.03
Beta
0.91

VTRS EPS Estimates vs Actual

Estimated
Actual

VTRS News & Sentiment

Dec 30, 2025 • openPR.com SOMEWHAT-BULLISH
Dementia Drugs Market 2025 Outlook: In-Depth Insights,
The global Dementia Drugs Market is projected to grow from US$26.14 Billion in 2025 to US$41.45 Billion by 2032, exhibiting a CAGR of 6.8%. This growth is driven by increasing industry demand and technological advancements, as highlighted in a new report by Coherent Market Insights. The report provides detailed insights into market dynamics, competitive landscapes, regional analysis, and identifies key companies and growth opportunities within the sector.
Dec 29, 2025 • FOX40 News BEARISH
Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders
A class action securities lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) by Levi & Korsinsky, LLP, on behalf of shareholders who suffered losses due to alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims that Viatris misrepresented the impact of a warning letter from the FDA regarding its Indore, India facility, leading to a significant stock price decline after the company released disappointing financial results and guidance for 2025. Shareholders are encouraged to learn about their rights to seek recovery.
Dec 28, 2025 • WJHL BEARISH
Investor Alert: Deadline Approaching to Join Viatris Inc. (VTRS) Class Action - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a class action securities lawsuit against Viatris Inc. (NASDAQ:VTRS) for shareholders who suffered losses due to alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter on its Indore, India facility, leading to a significant stock price drop following disappointing 2025 financial guidance. Investors are encouraged to contact the firm to learn about their rights to recovery without cost or obligation.
Dec 26, 2025 • WJBF NEUTRAL
Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders
A securities class action lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS), alleging that the company misled investors regarding the impact of a warning letter from the FDA concerning its Indore, India facility. Shareholders who suffered losses due to Viatris's stock decline on February 27, 2025, following disappointing financial results and revised guidance attributed to the FDA warning, are encouraged to contact Levi & Korsinsky for potential recovery. The firm represents shareholders and seeks to recover losses from alleged securities fraud between August 8, 2024, and February 26, 2025.
Dec 25, 2025 • 富途牛牛 BULLISH
Viatris Inc. Stock Climbs 1.8%, Outperforms Market
Viatris Inc. (VTRS) saw its stock climb 1.83%, outperforming the overall market. Concurrently, Unity Software (U.US) reported robust fourth-quarter financial results, with revenue increasing 35% year-over-year to $609 million, significantly exceeding analyst estimates. However, Unity still posted a quarterly loss of 66 cents per share.
Dec 24, 2025 • MSN NEUTRAL
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. (VTRS) stock saw a gain of 2.15% on Wednesday, closing at $11.85, which outperformed the broader market's daily decline. Despite this daily gain, the stock remains below both its 52-week high and its 50-day moving average.
Sentiment Snapshot

Average Sentiment Score:

0.060
50 articles with scored sentiment

Overall Sentiment:

Neutral

VTRS Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.07 Surprise
  • Reported EPS: $0.62
  • Estimate: $0.55
  • Whisper:
  • Surprise %: 12.7%
May 08, 2025
Mar 31, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $0.50
  • Estimate: $0.49
  • Whisper:
  • Surprise %: 1.6%
Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $0.54
  • Estimate: $0.57
  • Whisper:
  • Surprise %: -5.6%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.07 Surprise
  • Reported EPS: $0.75
  • Estimate: $0.68
  • Whisper:
  • Surprise %: 10.3%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $0.69
  • Estimate: $0.68
  • Whisper:
  • Surprise %: 1.5%
May 09, 2024
Mar 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.67
  • Estimate: $0.67
  • Whisper:
  • Surprise %: 0.0%
Feb 28, 2024
Dec 31, 2023 (Pre market)
-0.03 Surprise
  • Reported EPS: $0.62
  • Estimate: $0.65
  • Whisper:
  • Surprise %: -4.6%
Nov 07, 2023
Sep 30, 2023 (Post market)
0.05 Surprise
  • Reported EPS: $0.79
  • Estimate: $0.74
  • Whisper:
  • Surprise %: 6.8%
Aug 07, 2023
Jun 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $0.75
  • Estimate: $0.71
  • Whisper:
  • Surprise %: 5.6%

Financials